16.04.2018
![]()
DGAP-News: STADA Arzneimittel AG: Changes in the management team of STADA
DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous/Miscellaneous
STADA Arzneimittel AG: Changes in the management team of STADA
16.04.2018 / 19:12
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- Miguel Pagan to be new Member of the Executive Board for Production and
Development
- Steffen Wagner to be Head of Europe
- Carsten Cron to head Emerging Markets
- Robert Knerr to follow Wolter Kuizinga as Head of Business Development
Bad Vilbel, April 16, 2018 - STADA Arzneimittel AG ("STADA") is
systematically pushing ahead with the new strategy announced in March. Under
this strategy, the Company's focus is on the three pillars of generics,
non-prescription brands and specialty pharmaceuticals such as biosimilars,
together with efficiency gains in internal processes. "In order to implement
this new strategic orientation as efficiently as possible, we have decided,
together with the Supervisory Board, to effect a number of changes on the
top management level," said CEO Dr. Claudio Albrecht.
The previous Chief Production and Development Officer, Dr. Barthold Piening,
is to be followed by Spanish-born Miguel Pagan (53) as Member of the
Executive Board for Technical Operations.
The appointment of Dr. Barthold Piening as a Member of the Executive Board
of STADA has been mutually cancelled with immediate effect. Dr. Piening will
leave STADA end of May 2018 in order to pursue new career opportunities.
STADA thanks Dr. Piening for his dedicated service and great commitment
during a phase that brought many changes for STADA, as well as for the
excellent collaboration, in particular during the last months. The Executive
Board and Supervisory Board wish him all the best for his future endeavours.
Miguel Pagan was most recently Head of Global Technical Operations at SANDOZ
and Global Head of Solids & Special Tech for overall Novartis. Before that,
he was Head of all Operations of SANDOZ in Europe and India and previously
Vice President of Americas Operations at Merck (MSD). "We are pleased to
have gained a proven production and operations expert for STADA in Miguel
Pagan. He has many years of experience in managing international production
networks in large pharmaceutical groups and will further strengthen our
management team," said Dr. Günter von Au, Chairman of the Supervisory Board.
In addition, STADA has appointed three new members to its broader management
team. Dr. Steffen Wagner (40) is to become Head of Europe effective July 1,
2018. He was most recently Managing Director of Biogen Germany and will take
charge of all European markets except for Germany, the United Kingdom and
Russia.
STADA also appointed a new Head of Emerging Markets in Carsten Cron. The
47-year-old comes from Pfizer, where he was most recently Country Manager
for Morocco, Tunisia and Libya and also Commercial & Business Operations
Lead for North Africa and the Middle East. To date, the Head of Europe and
Head of Emerging Markets roles have both been fulfilled by CEO Albrecht.
A further change is made in the Business Development division. Wolter
Kuizinga had newly established this key strategic area of the Company,
making important settings of the course while heading it on an interim
basis. He is to be succeeded, at the latest from September 1, by the current
Vice President Portfolio Management, Dr. Robert Knerr. "This appointment
underscores our approach of filling more key positions at STADA with highly
qualified internal candidates going forward," said Albrecht. As the
successor to Knerr in Portfolio Management, STADA has recruited Dr. Stefan
Busemann, who is joining the Company from SANDOZ.
Contact:
STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße
2-18 / 61118 Bad Vilbel /
Tel.: +49 (0) 6101 603-173 [IMAGE] / Fax: +49 (0) 6101 603-215 [IMAGE] /
E-mail: [email protected]
Or visit us in the Internet at www.stada.com.
---------------------------------------------------------------------------
16.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: [email protected]
Internet: www.stada.de
ISIN: DE0007251803, ,
WKN: 725180, ,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
675043 16.04.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
STADA Arzneimittel AG ISIN: DE0007251803 können Sie bei DGAP abrufen
Gesundheit , 725180 , SAZ , XETR:SAZ